Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Galapagos ( (GLPG) ) just unveiled an announcement.
On March 6, 2026, Galapagos NV’s board approved “Subscription Right Plan 2026,” creating 1,750,000 subscription rights for current and potential future employees, each entitling the holder to subscribe to one new Galapagos share. The move expands the company’s equity-based compensation pool and may increase the total share count over time, aligning employee incentives with shareholder interests.
Following the adoption of the new plan, Galapagos reported that its existing share capital stands at €356,444,938.61 with 65,897,071 shares and voting rights outstanding, all in a single class. In addition to the new grant, the company has 13,338,810 subscription rights outstanding under other employee plans and a separate right issued to Gilead Therapeutics that can raise Gilead’s stake to 29.9%, underscoring the potential for future dilution and the strategic role of Gilead as a key shareholder.
The most recent analyst rating on (GLPG) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
GLPG scores strongest on financial positioning (very low leverage and large cash resources) and supported valuation (low P/E). The main offset is persistent negative operating/free cash flow and earnings quality concerns highlighted by non-recurring profit drivers and ongoing restructuring/wind-down cash needs; technical signals are broadly neutral.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a biotechnology company focused on developing meaningful medicines for patients with serious diseases in therapeutic areas of unmet medical need. The company applies a modality-agnostic asset selection strategy and emphasizes programs in oncology and immunology & inflammation that have clear clinical proof-of-concept, leveraging its capital and deal-making capabilities to acquire and advance promising assets.
Average Trading Volume: 106,600
Technical Sentiment Signal: Buy
Current Market Cap: $2.21B
See more insights into GLPG stock on TipRanks’ Stock Analysis page.